
|Videos|December 26, 2016
Access to PCSK9 Inhibitors Remains a Challenge
Author(s)Lauren Santye, Assistant Editor
Erin Hohman, PharmD, BCPS, director of Clinical Pharmacy Services at Amber Pharmacy, discusses challenges in gaining access to cholesterol-lowering PCSK9 inhibitors.
Advertisement
Erin Hohman, PharmD, BCPS, director of Clinical Pharmacy Services at Amber Pharmacy, discusses challenges in gaining access to cholesterol-lowering PCSK9 inhibitors.
Newsletter
Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Pharmacy Times
1
Polycystic Ovary Syndrome Undergoes Name Change: Polyendocrine Metabolic Ovarian Syndrome
2
Amid Mounting Pressure, FDA Commissioner Marty Makary to Resign
3
GLP-1 Receptor Agonists Linked to Improved Survival Outcomes in Breast Cancer
4
From Misdiagnosis to Advocacy: Addressing Bias and Equity in Heart Failure Management
5


































































































































